SteelPeak Wealth LLC Sells 29,555 Shares of Johnson & Johnson $JNJ

SteelPeak Wealth LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 27.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,261 shares of the company’s stock after selling 29,555 shares during the quarter. SteelPeak Wealth LLC’s holdings in Johnson & Johnson were worth $14,326,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Retirement Guys Formula LLC raised its position in Johnson & Johnson by 66.8% during the third quarter. Retirement Guys Formula LLC now owns 14,256 shares of the company’s stock valued at $2,639,000 after purchasing an additional 5,708 shares in the last quarter. Relyea Zuckerberg Hanson LLC boosted its holdings in shares of Johnson & Johnson by 11.5% in the 3rd quarter. Relyea Zuckerberg Hanson LLC now owns 31,504 shares of the company’s stock valued at $5,841,000 after purchasing an additional 3,259 shares in the last quarter. Lazard Freres Gestion S.A.S. acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $1,101,000. Sterling Investment Counsel LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $768,000. Finally, Three Magnolias Financial Advisors LLC boosted its stake in Johnson & Johnson by 12.6% in the third quarter. Three Magnolias Financial Advisors LLC now owns 7,166 shares of the company’s stock valued at $1,329,000 after buying an additional 800 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $207.26 on Monday. The stock has a market cap of $499.35 billion, a price-to-earnings ratio of 20.01, a P/E/G ratio of 2.13 and a beta of 0.34. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18. The company’s fifty day moving average is $201.17 and its 200 day moving average is $183.07. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Scotiabank assumed coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price for the company. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. UBS Group increased their price target on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Finally, Barclays boosted their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 30th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $211.25.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.